Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/81589
| Title: | Development of a novel quinoline derivative as a P-glycoprotein inhibitor to reverse multidrug resistance in cancer cells | Authors: | Zhou, Y Chung, PY Ma, JYW Lam, AKY Law, S Chan, KW Chan, ASC Li, X Lam, KH Chui, CH Tang, JCO |
Issue Date: | 2019 | Source: | Biology, 2019, v. 8, no. 4, 75 | Abstract: | Multidrug resistance (MDR) is one of conventional cancer chemotherapy’s limitations. Our group previously synthesized a series of quinoline-based compounds in an attempt to identify novel anticancer agents. With a molecular docking analysis, the novel compound 160a was predicted to target p-glycoprotein, an MDR candidate. The purpose of this study is to evaluate 160a’s MDR reversal effect and investigate the underlying mechanism at the molecular level. To investigate 160a’s inhibitory effect, we used a series of parental cancer cell lines (A549, LCC6, KYSE150, and MCF-7), the corresponding doxorubicin-resistant cell lines, an MTS cytotoxicity assay, an intracellular doxorubicin accumulation test, and multidrug resistance assays. The Compusyn program confirmed, with a combination index (CI) value greater than 1, that 160a combined with doxorubicin exerts a synergistic effect. Intracellular doxorubicin accumulation and transported calcein acetoxymethyl (AM) (a substrate for p-glycoprotein) were both increased when cancer cells with MDR were treated with compound 160a. We also showed that compound 160a’s MDR reversal effect can persist for at least 1 h. Taken together, these results suggest that the quinoline compound 160a possesses high potential to reverse MDR by inhibiting p-glycoprotein-mediated drug efflux in cancer cells with MDR. | Keywords: | Anticancer Multidrug resistance P-glycoprotein Quinoline compounds |
Publisher: | MDPI AG | Journal: | Fire safety journal | ISSN: | 2079-7737 | EISSN: | 2079-7737 | DOI: | 10.3390/biology8040075 | Rights: | © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). The following publication Zhou, Y., Chung, P. Y., Ma, J. Y. W., Lam, A. K. Y., Law, S., Chan, K. W., ... & Tang, J. C. O. (2019). Development of a Novel Quinoline Derivative as a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells. Biology, 8(4), 75 is available at https://doi.org/10.3390/biology8040075 |
| Appears in Collections: | Journal/Magazine Article |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Zhou_Development_Novel_Quinoline.pdf | 4.3 MB | Adobe PDF | View/Open |
Access
View full-text via PolyU eLinks 
Page views
54
Last Week
1
1
Last month
Citations as of May 28, 2023
Downloads
62
Citations as of May 28, 2023
SCOPUSTM
Citations
5
Citations as of May 25, 2023
WEB OF SCIENCETM
Citations
4
Citations as of May 25, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.